Stocks TelegraphStocks Telegraph
Stock Ideas

TOVX Company Profile and Key Details

AMEX : TOVX

Theriva Biologics

$0.43
0.1748+67.96%
Open: 11:04 AM
59.84
BESG ScoreESG Rating
ProfileKey StatsAnalyst RatingsOwnershipRatiosFinancialsDividend & splitsSentimentForecast

Price Chart

Stock Price Today

Theriva Biologics, Inc. (TOVX) stock surged +67.96%, trading at $0.43 on AMEX, up from the previous close of $0.26. The stock opened at $0.44, fluctuating between $0.40 and $0.49 in the recent session.

Stock Snapshot

0.2572
Prev. Close
15.42M
Market Cap
0.401
Day Low
-0.21
P/E Ratio
-2.08
EPS (TTM)
-1.12
Cash Flow per Share
0.44
Open
35.69M
Number of Shares
0.492
Day High
99.86%
Free Float in %
2.31
Book Value
416.42M
Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing DateAccepted Date

Annual Report (10-k)

Filing DateAccepted Date

Stock Price History Chart

DateOpenHighLowCloseVolume
Apr 17, 20260.260.260.250.261.38M
Apr 16, 20260.260.270.250.252.3M
Apr 14, 20260.270.270.240.241.98M
Apr 13, 20260.230.260.220.252.28M
Apr 10, 20260.240.250.230.231.89M
Apr 09, 20260.280.280.240.265.15M
Apr 08, 20260.260.310.250.3010.85M
Apr 07, 20260.240.260.240.254.23M
Apr 06, 20260.230.260.230.258.18M
Apr 02, 20260.220.230.220.233.05M
Apr 01, 20260.190.240.190.2311.42M
Mar 31, 20260.190.200.180.202.01M
Mar 30, 20260.200.200.180.193.01M
Mar 27, 20260.220.220.200.202.79M
Mar 25, 20260.220.240.210.229.64M
Mar 24, 20260.200.230.200.2122.17M
Mar 23, 20260.280.280.210.21254M
Mar 20, 20260.190.190.180.191.77M
Mar 19, 20260.180.190.180.191.46M
Mar 18, 20260.180.190.180.181.65M

Contact Details

Rockville, MD 20850

United States

https://therivabio.com301 417 4364

About Company

Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral �-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. The company was formerly known as Synthetic Biologics, Inc. and changed its name to Theriva Biologics Inc. in October 2022. Theriva Biologics Inc. is headquartered in Rockville, Maryland.

Company Information

Employees20
Beta0.52
Sales or Revenue$0.00
5Y Sales Change%0%
Fiscal Year EndsDecember
SectorHealthcare
IndustryBiotechnology

Stock Peers

TBXU
0.4306+1.34%
Direxion Daily Biotech Top 5 Bull 2X ETF$32.56PTHS
-0.05-0.22%
Pelthos Therapeutics Inc.$22.95PTN
1.6+7.66%
Palatin Technologies, Inc.$22.50ARMP
0.12+1.05%
Armata Pharmaceuticals, Inc.$11.50AGE
-1.5-11.90%
AgeX Therapeutics, Inc.$11.10CYBN
0.1+1.22%
Cybin Inc.$8.28NRXS
-0.14-1.90%
NeurAxis, Inc.$7.22CVM
0.31+6.68%
CEL-SCI Corporation$4.95CANF
-0.04-1.30%
Can-Fite BioPharma Ltd.$3.04PLX
0.02+0.87%
Protalix BioTherapeutics, Inc.$2.32

Company Overview

The stock is currently mid-range between its 52-week high and low $0.16 and $1.50. With a market capitalization of about $9.18 million, Theriva Biologics, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.47). Key stats such as the average daily volume over the past year has been around 13.95 million shares, volume is running light vs its 52-week average. Headquartered in Rockville, MD, Theriva Biologics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Steven A. Shallcross, the company employs approximately 20 people and listed since December 18, 2006. Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need.

Technical Performance

TOVX has shown weak momentum, losing -16.97% over the past week and -57.02% over the past quarter, though year-to-date performance is down -13.97%. Short-term trend indicators are bullishly aligned (SMA20 3.89%, SMA50 -0.84%, SMA200 -43.98%). The stock’s 14-day RSI is 50.88 (neutral), while the ATR of 0.02 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -86.87% below its high and over 21.01% above its low. Average 10-day trading volume of 1.97 million shares is below the 3-month average of 12.77 million, indicating normal recent market interest.

Valuation Metrics

Theriva Biologics, Inc. trades at a P/E ratio of -0.12, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.2 suggesting the stock is closer to book value. The P/FCF stands at -0.55, also below market averages.

Dividend & Fair Value

Theriva Biologics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.86. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Theriva Biologics, Inc. generated EPS of -$5.54 over the past year. Five-year average earnings growth is 39.99%. Wall Street analysts project EPS growth of 51.81% annually over the next five years. The latest quarter delivered EPS of -$0.45. The next quarter is forecast at -$0.50. Next year's EPS is expected at $21.01. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $1.00 to $1.00. The high target offers 284.62% upside. The low target suggests 284.62% downside. The mean target is $1.00. This offers 284.62% upside. Theriva Biologics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 18.6%. The prior quarter beat by 407.89%. Over the last six quarters, Apple has recorded several small beats. These include -21.43% in August 13, 2024.

Shareholding & Insider Activity

Theriva Biologics, Inc. has 9.60 million shares outstanding. The public float is 9.58 million shares, elevated short interest at 5.20% of float. This equals 498.20 thousand shares. The short ratio is 0.49 days. Institutional investors hold 2.91% of the float. Insiders own 1.63%.

Price Forecast & Outlook

Our AI price prediction model suggests that Theriva Biologics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 8.86%, with price expected at $0.28 by May 01, 2026, within a range of $0.26 to $0.30 3-Month Outlook: Projected fall of -88.34%, reaching $0.03 by July 16, 2026, with a range of $0.00 to $0.10. 1-Year Outlook: Projected loss of -84.45%, with price at $0.04 by April 16, 2027, within a range of $0.00 to $0.23.

Key Takeaways

Theriva Biologics, Inc. (AMEX:TOVX) shares are down -13.97% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Theriva Biologics, Inc. trading at a premium to the broader market with a P/E of -0.12. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $1.00, suggesting 288.8% upside. Our AI forecast model points to short-term strength (8.86% over two weeks), a medium-term fall (-88.34% over three months), and a longer-term loss (-84.45% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Theriva Biologics, Inc. (TOVX) stock price?
Theriva Biologics, Inc. (AMEX: TOVX) stock price is $0.43 in the last trading session. During the trading session, TOVX stock reached the peak price of $0.49 while $0.40 was the lowest point it dropped to. The percentage change in TOVX stock occurred in the recent session was 67.96% while the dollar amount for the price change in TOVX stock was $0.17.
TOVX's industry and sector of operation?
The AMEX listed TOVX is part of Biotechnology industry that operates in the broader Healthcare sector. Theriva Biologics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of TOVX?
No Data
How TOVX did perform over past 52-week?
TOVX's closing price is 60.75% higher than its 52-week low of $0.16 where as its distance from 52-week high of $1.50 is -82.85%.
How many employees does TOVX have?
Number of TOVX employees currently stands at 20.
Link for TOVX official website?
Official Website of TOVX is: https://therivabio.com
How do I contact TOVX?
TOVX could be contacted at phone 301 417 4364 and can also be accessed through its website. TOVX operates from 9605 Medical Center Drive, Rockville, MD 20850, United States.
How many shares of TOVX are traded daily?
TOVX stock volume for the day was 416.42M shares. The average number of TOVX shares traded daily for last 3 months was 15.19M.
What is the market cap of TOVX currently?
The market value of TOVX currently stands at $15.42M with its latest stock price at $0.43 and 35.69M of its shares outstanding.
logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

About

HomeAboutMeet The TeamContact UsPrivacy PolicyNewsletter

Useful Links

ScreenerMarket DataInsider TransactionsUpgrades & Downgrades52 Week Highs & LowsUnusual VolumeDividend CalendarEarnings CalendarStocks Watchlist
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph